Sjögren's Syndrome Management
Diagnostic Approach
- The American College of Rheumatology recommends obtaining anti-SSA/Ro and anti-SSB/La antibodies to confirm diagnosis and assess disease severity, as anti-Ro positivity scores 3 points toward diagnostic criteria and has prognostic implications 1, 4
- The European League Against Rheumatism (EULAR) suggests calculating ESSDAI (EULAR Sjögren's Syndrome Disease Activity Index) to quantify systemic disease activity and guide treatment intensity 2, 3
Treatment Algorithm
- For patients with low disease activity (ESSDAI 1-4), the American Academy of Ophthalmology recommends managing sicca symptoms with topical therapies, such as artificial tears, and considering hydroxychloroquine for fatigue and arthralgias 1, 6, 7
- For patients with moderate disease activity (ESSDAI 5-13), the American College of Rheumatology recommends initiating glucocorticoids at minimum effective dose and adding steroid-sparing agents, such as azathioprine or methotrexate, for maintenance therapy 2, 3, 6
- For patients with severe or refractory disease, the European League Against Rheumatism (EULAR) suggests considering rituximab, particularly when hyperglobulinemia is associated with cryoglobulinemia, vasculitis, or lymphoma risk 2, 5
Monitoring Requirements
- The American Thoracic Society recommends repeating pulmonary function tests (PFTs) every 6-12 months to track pulmonary disease trajectory if baseline abnormalities are present 8, 3
- The American College of Rheumatology suggests monitoring for lymphadenopathy, fevers, and night sweats at each visit, as 2-5% of patients with Sjögren's syndrome develop lymphoma 3
- The European League Against Rheumatism (EULAR) recommends reassessing ESSDAI at regular intervals to guide treatment adjustments, with therapeutic response defined as ≥3 point reduction in global ESSDAI score 3